New study: Tocilizumab in the Treatment of Pulmonary Arterial Hypertension 6th May 2016
New study: A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
Inflammation and autoimmunity have an important role in Pulmonary Hypertension, a serious condition characterised by raised blood pressure in the arteries of the lung. Interleukin-6 (IL6) is a protein which assists the body's immune response. Tocilizumab is an immunosuppressant drug which blocks the IL6 receptor therefore decreasing its effects on the immune system, and has been shown to be safe and effective in treatment of rheumatoid arthritis.
The UK pulmonary hypertension treatment centres are collaborating in a new phase 2 clinical trial, which will investigate the effectiveness of Tocilizumab treatment in people with PAH. The Pulmonary Vascular Disease Unit based at the Royal Hallamshire will undertake this study, supported by the Clinical Research Facility. For further information please contact email@example.com